475 related articles for article (PubMed ID: 26715803)
1. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.
Androulakis I; Zavos C; Christopoulos P; Mastorakos G; Gazouli M
World J Gastroenterol; 2015 Dec; 21(47):13205-11. PubMed ID: 26715803
[TBL] [Abstract][Full Text] [Related]
2. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
3. Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION).
Luu M; Benzenine E; Doret M; Michiels C; Barkun A; Degand T; Quantin C; Bardou M
Am J Gastroenterol; 2018 Nov; 113(11):1669-1677. PubMed ID: 29961771
[TBL] [Abstract][Full Text] [Related]
4. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.
George LA; Gadani A; Cross RK; Jambaulikar G; Ghazi LJ
Dig Dis Sci; 2015 Nov; 60(11):3424-30. PubMed ID: 26115749
[TBL] [Abstract][Full Text] [Related]
5. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
[TBL] [Abstract][Full Text] [Related]
6. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate for inflammatory bowel disease: time for reconsideration.
Nielsen OH; Ainsworth MA; Steenholdt C
Expert Rev Gastroenterol Hepatol; 2019 May; 13(5):407-409. PubMed ID: 30895827
[No Abstract] [Full Text] [Related]
8. Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre study.
Bazzani C; Scrivo R; Andreoli L; Baldissera E; Biggioggero M; Canti V; Gerosa M; Pontikaki I; Ramoni V; Trespidi L; Zatti S; Caporali R; Gorla R; Iannone F; Lojacono A; Meroni P; Montecucco C; Motta M; Sabbadini MG; Valesini G; Tincani A
Clin Exp Rheumatol; 2015; 33(5):688-93. PubMed ID: 26311348
[TBL] [Abstract][Full Text] [Related]
9. Biologic Agents Are Associated with Excessive Weight Gain in Children with Inflammatory Bowel Disease.
Haas L; Chevalier R; Major BT; Enders F; Kumar S; Tung J
Dig Dis Sci; 2017 Nov; 62(11):3110-3116. PubMed ID: 28895012
[TBL] [Abstract][Full Text] [Related]
10. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
[TBL] [Abstract][Full Text] [Related]
11. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
12. A Narrative Review on Anti-Tumor Necrosis Factor α Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact.
Roseira J; Ramos J
Acta Med Port; 2019 Apr; 32(4):305-312. PubMed ID: 31067425
[TBL] [Abstract][Full Text] [Related]
13. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.
Mahadevan U; Cucchiara S; Hyams JS; Steinwurz F; Nuti F; Travis SP; Sandborn WJ; Colombel JF
Am J Gastroenterol; 2011 Feb; 106(2):214-23; quiz 224. PubMed ID: 21157441
[TBL] [Abstract][Full Text] [Related]
14. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
[TBL] [Abstract][Full Text] [Related]
15. Treating Inflammatory Bowel Disease in Pregnancy: The Issues We Face Today.
Damas OM; Deshpande AR; Avalos DJ; Abreu MT
J Crohns Colitis; 2015 Oct; 9(10):928-36. PubMed ID: 26129693
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases.
Billmeier U; Dieterich W; Neurath MF; Atreya R
World J Gastroenterol; 2016 Nov; 22(42):9300-9313. PubMed ID: 27895418
[TBL] [Abstract][Full Text] [Related]
17. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.
Khan N; Asim H; Lichtenstein GR
Expert Opin Drug Saf; 2014 Dec; 13(12):1699-708. PubMed ID: 25406728
[TBL] [Abstract][Full Text] [Related]
18. Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes?
Mosli M; Alfaer S; Almalaki T; Albeshry A; Aljehani S; Alshmrani B; Habib Z; Jawa H; Qari Y
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):80-85. PubMed ID: 30199472
[TBL] [Abstract][Full Text] [Related]
19. Surgery for Crohn's disease and anti-TNF agents: the changing scenario.
Sorrentino D; Fogel S; Van den Bogaerde J
Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):689-700. PubMed ID: 24161133
[TBL] [Abstract][Full Text] [Related]
20. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]